



New Advances in Pathogenesis and Treatment of HIV Infection: Molecular Insight and Preclinic Research

Guest Editors:

Prof. Dr. Alessandro Russo

Department of Medical and Surgical Sciences, Infectious and Tropical Disease Unit, "Magna Graecia" University of Catanzaro, 88100 Catanzaro, Italy

Dr. Gabriella D'Ettore

1. Department of Public Health and Infectious Diseases, University of Rome "Sapienza", Rome, Italy
2. Azienda Policlinico Umberto I, 00161 Rome, Italy

Dr. Giancarlo Ceccarelli

Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy

Deadline for manuscript submissions:

closed (15 May 2022)

Message from the Guest Editors

Infection caused by human immunodeficiency virus (HIV) remains one of the most important challenges for researchers and requires the development of strategies and effective cures.

The spectrum of diseases associated with HIV ranges from opportunistic infections and cancers to systemic physiological disorders such as encephalopathy and neurocognitive impairment. Over the last few years, much progress in controlling HIV infection has been made by highly active antiretroviral therapy (HAART). However, HAART neither eliminates the virus reservoirs in the form of latently infected cells nor completely reconstitutes the immune reactivity and physiological status. Furthermore, the causal relationships between the complex sets of viral and immunological processes that contribute to protection or disease pathogenesis remain poorly understood.

The aim of this Special Issue is to publish high-quality research on the pathogenesis and treatment of HIV. This research will contribute to the development of new methodologies for analysis and therapy, and to the prediction of the functional restoration of the immune system and the health of the infected host.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)